Clinical Efficacy of Modified Dunfutang for Spleen-kidney Yang Deficiency Type Ankylosing Spondylitis

GU Hui-min; MENG Qing-liang; ZUO Rui-ting; DU Xu-zhao; WANG Hui-lian; ZHOU Zi-peng; MIAO Xi-yun; FAN Wei

doi:10.13422/j.cnki.syfjx.20182325

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Modified Dunfutang for Spleen-kidney Yang Deficiency Type Ankylosing Spondylitis

更新时间：2024-09-23

- Clinical Efficacy of Modified Dunfutang for Spleen-kidney Yang Deficiency Type Ankylosing Spondylitis
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 24, Pages: 177-183(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20182325
  CLC： R259
- Published：2018
- 稿件说明：
移动端阅览
GU Hui-min, MENG Qing-liang, ZUO Rui-ting, et al. Clinical Efficacy of Modified Dunfutang for Spleen-kidney Yang Deficiency Type Ankylosing Spondylitis[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(24): 177-183.
DOI：

GU Hui-min, MENG Qing-liang, ZUO Rui-ting, et al. Clinical Efficacy of Modified Dunfutang for Spleen-kidney Yang Deficiency Type Ankylosing Spondylitis[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(24): 177-183. DOI： 10.13422/j.cnki.syfjx.20182325.

摘要

目的：观察敦复汤加减治疗脾肾阳虚型强直性脊柱炎（PSYXAS）的疗效及安全性。方法：将209例PSYXAS患者随机分为中药组（69例）、西药组（67例）和中西药组（73例）。中药组给予敦复汤加减治疗，西药组给予双氯芬酸钠缓释片治疗，中西药组同时给予敦复汤加减和双氯芬酸钠缓释片，疗程均为63 d。比较各组治疗前后脊柱疼痛视觉模拟评分（VAS）

活动度衡量指数（BASMI），疾病功能指数（BASFI）、患者整体评分（PGA）和中医辨证脾肾阳虚证评分；检测治疗前后C反应蛋白（CRP），血沉（ESR），肿瘤坏死因子-α（TNF-α）和血小板（PLT）的变化；比较各组有效率及不良反应发生率。结果：治疗后中西药组总有效率93.1%，显著高于中药组的75.4%和西药组的71.6%（P<0.01）；与西药组相比，中药组和中西药组脾肾阳虚证评分改善更为明显（P<0.05）；其他临床症状中西药组评分改善均较中药组和西药组改善更为明显（P<0.05），中药组与西药组之间则无显著差异；不良反应的发生率中药组（1.45%，1/69）结论：敦复汤加减治疗PSYXAS的疗效与西药双氯芬酸钠缓释片无明显差异，具有效性，且不良反应的发生率较双氯芬酸钠缓释片低。敦复汤加减结合双氯芬酸钠缓释片治疗PSYXAS疗效优于西药双氯芬酸钠缓释片。

Abstract

Objective: To observe the therapeutic effect and safety of modified Dunfutang in treatment of spleen-kidney Yang deficiency type ankylosing spondylitis (PSYXAS)

and investigate its possible mechanism. Method: A total of 209 PSYXAS patients were randomly divided into Chinese medicine group (69 cases)

western medicine group (67 cases) and integrated Chinese and western medicine group (73 cases). Patients in Chinese medicine group were treated with Dunfutang; patients in western medicine group were treated with diclofenac sodium sustained release tablets; and patients in integrated Chinese and western medicine group received Dunfutang and diclofenac sodium sustained release tablets

with a treatment course of 63 d in all groups.Then the spinal pain visual analogue scale (VAS) scores

bath ankylosing spondylitis metroloty index (BASMI)

bath ankylosing spondylitis functional index (BASFI)

patient global assessment (PGA)

and traditional Chinese medicine(TCM) spleen-kidney Yang deficiency syndrome scores were compared before and after treatment. The changes of C-reactive protein (CRP)

erythrocyte sedimentation rate (ESR)

tumor necrosis factor alpha (TNF-α) and platelet (PLT) were detected. Effective rate and incidence of adverse reactions were compared between various groups. Result: The total effective rate was 93.1% in integrated Chinese and western medicine group

significantly higher than 75.4% in Chinese medicine group and 71.6% in western medicine group (P<0.01). As compared with western medicine group

spleen-kidney Yang deficiency syndrome scores were improved more significantly in Chinese medicine group and the Chinese and western medicine group (P<0.05). For the other clinical symptom scores

the improvement in integrated Chinese and western medicine group was more obvious than that in Chinese medicine group and western medicine group (P<0.05) but with no significant difference between Chinese medicine group and western medicine group. The incidence of adverse reactions was as follows:Chinese medicine group (1.45%

1/69) < integrated Chinese and western medicine group (8.22%

6/73) < western medicine group (16.42%

11/67). Conclusion: Dunfutang and western medicine diclofenac lysine sustained release tablet have no significant difference in clinical efficacy for treatment of PSYXAS

and the incidence of adverse reactions of Dunfutang is lower than that of western medicine. In addition

Dunfutang combined with diclofenac lysine sustained release tablet has a better efficacy than diclofenac lysine sustained release tablet alone in the treatment of PSYXAS.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Effect of Youguitang for Kidney Deficiency and Cold Type Ankylosing Spondylitis

Effect of Wulao Qisun Prescription on Proliferation and Osteogenic Differentiation of AS Fibroblasts by Regulating Wnt/β-catenin Signaling Pathway

Research Progress on Pathogenesis of Ankylosing Spondylitis and Intervention of Traditional Chinese Medicine： A Review

Zhenwutang Ameliorates Diabetic Kidney Disease in Mice with Spleen-kidney Yang Deficiency via Nrf2/HO-1/GPX4 Signaling Pathway

Sishenwan Combined with Tongxie Yaofang Treats Ulcerative Colitis with Spleen-kidney Yang Deficiency and Liver Depression

Related Author

GUO Zhong-hua

WAN Xiao-guan

DONG Sheng-jun

YANG Juanjuan

CHEN Ping

WANG Haidong

WANG Zhendong

LI Haolin

Related Institution

Gansu Provincial Hospital of Traditional Chinese Medicine

Clinical College of Chinese Medicine， Gansu University of Chinese Medicine

Gansu Provincial Hospital of TCM Rheumatism Osteopathy Center

Gansu University of Traditional Chinese Medicine （TCM）

Gansu Laboratory Animal Industry Technology Center

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰